clinicaltrialsarena1d
A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
On 26 September 2024, Bristol Myers Squibb (BMS) announced that the US Foof and Drug Administration approved Cobenfy ...
Medscape3d
Onset of Efficacy and Tolerability Following the Initiation Dosing of Long-acting Paliperidone Palmitate
With respect to tolerability concerns with the recommended paliperidone palmitate initiation dosing, this study did not reveal unexpected adverse events or high rates of specific adverse events in ...
JD Supra9d
Supreme Court of Canada to hear method of medical treatment appeal
On September 19, 2024, the Supreme Court of Canada granted Pharmascience leave to appeal a Federal Court of Appeal decision ...
Monthly Prescribing Reference2y
Invega Trinza
Paliperidone (as palmitate) 273mg, 410mg, 546mg, 819mg; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp ...
Medscape13y
Paliperidone ER and Oral Risperidone in Patients with Schizophrenia
Background: To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Methods: Six double-blind ...